PMS and PMDD: What a New Supplement Trial Shows, and What the Stronger Evidence Actually Says

This article is for educational purposes intended for healthcare practitioners and informed readers. It does not constitute medical advice. Premenstrual dysphoric disorder can involve significant mood symptoms, including suicidal ideation in a minority of cases, and anyone experiencing thoughts of self-harm should seek immediate help from a crisis service or emergency department.

Why This Trial Is Worth Reading

Premenstrual syndrome and its more severe counterpart, premenstrual dysphoric disorder, are among the most commonly self-treated conditions in naturopathic and integrative practice, and also among the most commercially crowded. Dozens of branded "PMS formulas" exist, most combining several herbs and nutrients into a single proprietary capsule, and most tested, if tested at all, only against their own ingredient list rather than against the individual components that make them up. A trial published in October 2025 in the Journal of Pharmaceutical Health Care and Sciences tested exactly one of these branded products, a ten-ingredient capsule called PMSoff, in a double-blind, placebo-controlled design. The result is a useful case study in how to read an industry-funded combination-product trial honestly, and it sets up a direct comparison with the individual ingredients that actually have the stronger, better-characterized trial evidence: Vitex agnus-castus (chasteberry), calcium, and vitamin B6.

The PMSoff Trial: Design, Funding, and What It Actually Tested

The study, "Natural relief for premenstrual syndrome (PMS): a double-blind clinical trial on the efficacy and safety of PMSoff," was conducted by Saghafi, Zare, Hatamizadeh, Malmir, and Sahebnasagh and published in the Journal of Pharmaceutical Health Care and Sciences on October 21, 2025. It was financially supported by Apira Arman Pirouz, the Iranian pharmaceutical company that markets PMSoff, a detail the authors disclose and that matters for how the results should be weighed.

PMSoff is a proprietary capsule combining ten active ingredients in a single dose: lavender extract, lesser dodder extract, valerian extract, spirulina extract, saffron extract, curcumin, chamomile extract, rose extract, calcium citrate, and vitamin B1. Two hundred fifty-five participants aged 14 to 30 were randomized, with 218 completing the trial (112 intervention, 106 placebo control), using simple random allocation with double-blinding of both participants and investigators. Dosing was two capsules daily, beginning seven days before expected menstruation and continuing through three days after onset, across three consecutive menstrual cycles over a 13-month recruitment window (February 2024 to March 2025). The primary outcome was PMS symptom severity measured by the Daily Record of Severity of Problems (DRSP), a validated self-report scale; a secondary analysis looked separately at the subgroup of participants who met criteria for PMDD.

A ten-ingredient proprietary blend cannot tell you which, if any, of its components is doing the work. Lavender, valerian, saffron, and chamomile each have some independent trial literature for anxiety or sleep, but a combination trial like this one is not designed to, and cannot, isolate an active ingredient. That is a structural limitation of the trial design itself, not a flaw unique to this study, and it applies to essentially every proprietary multi-ingredient PMS formula on the market.

What the Trial Found, and Why the Numbers Need Context

Across the full study population (n=218), DRSP scores fell in both the intervention and placebo arms over the three-cycle study period, which is itself expected: PMS symptom-tracking trials routinely show a placebo response, and symptom severity also naturally fluctuates cycle to cycle. The intervention group's additional improvement over placebo reached statistical significance only after the treatment had been running for some time: scores were not significantly different between groups at one month pre-intervention (p=0.06), reached significance at one month post-intervention (p=0.043), and were more clearly separated by two months post-intervention (p=0.001).

In the pre-specified PMDD subgroup (n=134), the picture was weaker. Group differences were not significant at one month pre-intervention (p=0.356) or one month post-intervention (p=0.410), and only reached significance at the two-month mark (p=0.044), a result close to the conventional 0.05 threshold. Adherence was reported at 72 percent in both arms. The authors themselves list several limitations worth taking at face value: no follow-up data beyond two months, non-probability convenience and snowball sampling that limits how representative the sample is, no item-level breakdown of which DRSP symptom domains (physical versus psychological) improved, a relatively small sample for a ten-ingredient product, a single-country Iranian population, and no molecular-level exploration of mechanism.

Put plainly, this is a positive but modest result, industry-funded, for a proprietary multi-ingredient product, with a borderline effect in the PMDD subgroup specifically. It supports PMSoff as plausibly better than placebo for general PMS symptom severity by two months of use. It does not establish which ingredient is responsible, does not strongly support efficacy for PMDD specifically, and should not be read as more definitive than a single, sponsor-funded, convenience-sampled trial actually is.

Where the Stronger Evidence Actually Sits: Vitex agnus-castus

Two of PMSoff's components, calcium and vitamin B1, overlap with nutrients that have been studied individually and in better-characterized form. Vitex agnus-castus (chasteberry), which is not in PMSoff's ingredient list but is the single most-studied natural agent for PMS, is a useful comparison point for what a firmer evidence base looks like.

A 2017 systematic review and meta-analysis by Verkaik, Kamperman, van Westrhenen, and Schulte, published in the American Journal of Obstetrics and Gynecology, identified 17 randomized controlled trials of Vitex agnus-castus for PMS, with 14 included in quantitative synthesis. Thirteen of 14 studies reported a positive effect on total PMS symptoms relative to placebo or comparators, and the pooled effect size was large (Hedges' g −1.21, 95% CI −1.53 to −0.88). The authors were explicit, however, that heterogeneity across the included trials was extremely high (I² = 91%), meaning the studies disagreed with each other substantially, and that risk of bias across the trial base was a genuine concern limiting how confidently the pooled effect can be read.

A separate 2019 meta-analysis by Csupor and colleagues, published in Complementary Therapies in Medicine, took a stricter approach: of 21 clinical trials screened, only 3 (520 women total) used sufficiently well-characterized Vitex preparations, specifically the standardized extracts Ze 440 and BNO 1095, to be included. Among those three higher-quality trials, women taking Vitex were 2.57 times more likely to achieve symptom remission than those on placebo (RR 2.57, 95% CI 1.52–4.35). The authors' own caveat is worth repeating directly: "the majority of the studies cannot be used as evidence for efficacy due to incomplete reporting, especially concerning the description of the used medication." In plain terms, most Vitex products sold have never been tested in a trial rigorous enough to count, and the real evidence base supports specific, standardized extracts rather than chasteberry as a generic category.

Calcium, Vitamin B6, and Zinc: The Broader Nutritional Evidence

A 2025 systematic review by Robinson, Ferreira, Iacovou, and Kellow, published in Nutrition Reviews, examined 31 randomized controlled trials (32 published articles, 3,254 participants aged 15 to 50) testing nutritional interventions against the psychological symptoms of PMS specifically. The review found that vitamin B6, calcium, and zinc each showed consistent, significant positive effects on psychological PMS symptoms across the included trials. Notably, the same review found insufficient evidence to support vitamin B1, vitamin D, whole-grain carbohydrates, soy isoflavones, dietary fatty acids, magnesium, multivitamin supplementation, or PMS-specific diets, an important distinction given how often magnesium in particular is recommended for PMS in naturopathic practice on the strength of its migraine and general muscle-relaxation evidence rather than PMS-specific trial data (our migraine prevention evidence review covers the separate, split evidence for magnesium in that context). The authors' overall quality assessment was blunt: only one of the included studies had a low risk of bias, and they called for more research "using consistent protocols, procedures to minimize risk of bias, intention-to-treat analysis, and clearer reporting" before firmer nutritional recommendations can be made.

An earlier, smaller randomized trial specifically testing combined calcium (500 mg) and vitamin B6 (40 mg), twice daily for two months, against vitamin B6 alone found a larger symptom reduction in the combination group, consistent with the broader systematic review's conclusion that calcium and B6 each contribute independently rather than one simply substituting for the other.

What the Evidence Does Not Support

Three things are worth stating plainly, because they are easy to blur in supplement marketing. First, a positive proprietary-blend trial like the PMSoff study does not transfer to other, differently formulated combination products, even ones sharing some ingredients. Second, "chasteberry works for PMS" is not the same claim as "any Vitex supplement works for PMS": the rigorous evidence specifically supports standardized extracts at doses matching the trials, not chasteberry as a generic category, and most commercial Vitex products have never been tested to that standard. Third, magnesium's reputation as a PMS remedy outruns the PMS-specific trial evidence, even though magnesium has better-supported uses elsewhere, including migraine prevention and the broader metabolic context discussed in our DUTCH test hormone testing guide for patients whose cyclical symptoms warrant a broader hormonal and adrenal workup before treatment selection.

Safety and Interaction Considerations

Vitex agnus-castus works at least in part through dopaminergic activity affecting prolactin and progesterone, which means it should be avoided or used only with specialist guidance alongside dopamine agonists or antagonists, including some antipsychotic and antiemetic medications, and alongside hormonal contraceptives or hormone-sensitive conditions, where its hormonal activity creates a theoretical interaction. The U.S. National Center for Complementary and Integrative Health notes chasteberry is generally well tolerated short-term, with mild effects such as nausea, stomach upset, diarrhea, headache, or itching, but flags it as unsafe in pregnancy and breastfeeding and not advised for women with hormone-sensitive cancers (breast, uterine, or ovarian). Calcium and vitamin B6 are comparatively low-risk at the doses studied, though vitamin B6 doses above roughly 100 mg per day sustained over long periods have been associated with peripheral neuropathy in case reports, which argues for staying within trial-supported dosing (commonly 50 to 80 mg per day) rather than higher self-directed doses. PMSoff's ten-ingredient formulation means a full interaction review of each component (notably saffron's documented but generally mild bleeding-risk profile and valerian's sedative additive effect with other CNS depressants) is warranted before recommending it to a patient on other medications.

Practical Implications for Naturopathic Practice

The honest summary is that a manufacturer-funded trial of a ten-ingredient proprietary product found a modest, time-delayed benefit for general PMS symptoms and a borderline result for PMDD specifically, which is a weaker result than the framing "clinically proven PMS relief" would suggest, and not strong enough on its own to justify recommending that specific branded product over its better-studied individual components. For a patient presenting with PMS, the firmer starting points remain a standardized Vitex extract (matching the Ze 440 or BNO 1095 preparations used in the higher-quality trial evidence) or calcium with vitamin B6 at trial-supported doses, both with meaningfully larger and more consistent trial support than the combination-product literature currently offers. For PMDD specifically, where symptoms are more severe and often include significant mood disturbance, the evidence for any single naturopathic intervention is thinner than for PMS generally, and this should be communicated to patients directly rather than implied away by extrapolating from PMS trial data. Ruling out an overlapping or mimicking hormonal pattern, such as the estrogen-progesterone imbalance discussed in our estrogen dominance protocol, is a reasonable step before attributing cyclical mood and physical symptoms to PMS or PMDD alone.

When to Refer or Escalate

PMDD is a recognized psychiatric diagnosis, not simply severe PMS, and any patient reporting suicidal ideation, significant functional impairment, or symptoms that do not improve with first-line nutritional and herbal approaches over two to three cycles should be referred for a formal psychiatric or gynecological assessment. SSRIs, used either continuously or only during the luteal phase, have stronger and more consistent trial evidence for PMDD than any natural intervention reviewed here, and should not be withheld or delayed in favor of a supplement trial, particularly where risk of self-harm is present. Chasteberry should not be combined with hormonal contraceptives, dopamine-affecting psychiatric medication, or used in pregnancy without specialist oversight, and any patient on psychiatric medication exploring a multi-ingredient product like PMSoff warrants a full medication interaction review before starting it.

Clinical Summary

A 2025 manufacturer-funded, double-blind RCT of a ten-ingredient proprietary supplement (PMSoff) found a modest, time-delayed reduction in PMS symptom severity (p=0.001 by two months) and a borderline effect in the PMDD subgroup (p=0.044 at two months only), with notable limitations including industry funding, convenience sampling, and no ability to isolate an active ingredient from the ten-component blend. Independently, standardized Vitex agnus-castus extracts have firmer, if still heterogeneous, trial support (large pooled effect in a 2017 meta-analysis of 14 trials; RR 2.57 in a stricter 2019 meta-analysis limited to 3 well-characterized trials), and a 2025 systematic review of 31 RCTs found consistent benefit for vitamin B6, calcium, and zinc on PMS psychological symptoms specifically, while finding insufficient evidence for magnesium, vitamin D, and several other commonly recommended nutrients in this context. PMDD, as a psychiatric diagnosis, warrants a lower threshold for referral and should not be managed on natural interventions alone when symptoms are severe or involve risk of self-harm.

References

• Saghafi F, Zare P, Hatamizadeh N, Malmir M, Sahebnasagh A. "Natural relief for premenstrual syndrome (PMS): a double-blind clinical trial on the efficacy and safety of PMSoff." Journal of Pharmaceutical Health Care and Sciences. 2025 Oct 21. DOI: 10.1186/s40780-025-00495-6. Full text: PMC12538989.
• Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. "The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis." American Journal of Obstetrics and Gynecology. 2017 Aug;217(2):150-166. PMID: 28237870.
• Csupor D, Lantos T, Hegyi P, et al. "Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials." Complementary Therapies in Medicine. 2019;47:102190. DOI: 10.1016/j.ctim.2019.08.024.
• Robinson J, Ferreira A, Iacovou M, Kellow NJ. "Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome in women of reproductive age: a systematic review of randomized controlled trials." Nutrition Reviews. 2025 Feb;83(2):280-306. DOI: 10.1093/nutrit/nuae043. Publication record: Monash University.
• National Center for Complementary and Integrative Health. "Chasteberry." Reviewed April 2025. nccih.nih.gov/health/chasteberry.

This article is intended for educational purposes and professional practice reference. It does not constitute individual medical advice. PMDD is a recognized psychiatric diagnosis; any patient with significant mood symptoms, functional impairment, or thoughts of self-harm should be assessed by a qualified healthcare provider, and natural interventions should be discussed with, not substituted for, a prescribing clinician's plan.